Analysis
Sanofi has successfully navigated the U.S. tariff landscape introduced in 2025, reaching a definitive agreement with the U.S. administration in December 2025 that largely neutralized the potential financial headwind. While the April 2025 "Liberation Day" tariffs initially created broad sector uncertainty, a specific 15% tariff on European pharmaceutical shipments to the U.S. materialized in July 2025. Sanofi mitigated the immediate impact on its FY2025 results by utilizing existing U.S. inventory and confirming that its established guidance already accounted for known trade measures, including those related to U.S.-China trade.
For FY2026, Sanofi management expects "minimal tariff impact" as a direct result of the December 2025 agreement with the U.S. government. During the January 2026 earnings call, CFO François-Xavier Roger described the resolution as a successful "cost avoidance" measure following "tough negotiations" (Transcript FY-2025). This agreement allows the company to maintain its gross margin expansion trajectory and support its FY2026 guidance for high single-digit sales growth and business EPS growth that outpaces sales.
The company's primary long-term mitigation strategy involves a strategic shift toward increasing its U.S. manufacturing footprint. Prior to the tariff announcements, Sanofi had already begun actively expanding its U.S. production capabilities, particularly for biologics drug substance (Transcript 2Q-2025). This localized production capacity, combined with the successful year-end negotiations, has allowed Sanofi to characterize the tariff issue as an "unnecessary drag" on its outlook that has now been addressed (Transcript Sept-2025).
Sources
Our gross margin expansion is expected to continue with minimal tariff impact following the agreement reached with the U.S. administration last December.
The tariff piece was an unnecessary drag on the thinking for 2026. [...] It was, like for everybody, a tough negotiation with the government. I think they got, I think, what they needed, but we felt well represented.
We confirmed we did not factor it in our guidance, but it will have a limited impact on 2025 because we already have inventory in place in the U.S.